Orbus Pharma Inc.

Orbus Pharma Inc.

July 31, 2006 16:49 ET

Orbus Signs Development, Manufacture and Supply Agreement

TORONTO, ONTARIO--(CCNMatthews - July 31, 2006) - Orbus Pharma Inc. (TSX:ORB) ("Orbus") today announced that they have entered into a development, manufacture and supply agreement with ratiopharm inc., of Mississauga, Ontario, to develop and supply a generic product used in the treatment of depression for the Canadian market.

Under the agreement, Orbus will manufacture the product at its Markham, Ontario plant and ratiopharm will file the Abbreviated New Drug Submission (ANDS) with Health Canada, and will market and distribute the generic drug product under the ratiopharm name in the Canadian market. Financial terms of the Agreement were not disclosed.

"We are pleased with this new collaboration" said Jeff Renwick, President and CEO of Orbus. "We believe this ten year supply agreement is the start of a long-term relationship with an important partner."

ratiopharm inc. is one of the leading generic pharmaceutical companies that develops, manufactures, markets and distributes generic pharmaceutical products, and is aiming to be the industry's most valued supplier of high quality generic products in the Canadian market.

Orbus Pharma Inc., listed on The Toronto Stock Exchange under the symbol ORB, pursues a strategy of generating revenue through the licensing of our generic drug developments as well as the manufacturing and selling of pharmaceutical products.

Contact Information

  • Orbus Pharma Inc.
    Jeffrey W. Renwick
    President and Chief Executive Officer
    (905) 943-9444